EMERGENT BIOSOLUTIONS INC. Capitalized Contract Cost, Amortization
EMERGENT BIOSOLUTIONS INC. (EBS) reported Capitalized Contract Cost, Amortization of $1.70 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:CapitalizedContractCostAmortization · last filed 2021-11-05
- EMERGENT BIOSOLUTIONS INC. capitalized contract cost, amortization for the quarter ending 2021-09-30 was $1.70M.
- EMERGENT BIOSOLUTIONS INC. capitalized contract cost, amortization for the quarter ending 2021-06-30 was $1.60M.
- EMERGENT BIOSOLUTIONS INC. capitalized contract cost, amortization for the quarter ending 2021-03-31 was $0.00.
| Period end | Capitalized Contract Cost, Amortization 3 month | Capitalized Contract Cost, Amortization 6 month | Capitalized Contract Cost, Amortization 9 month | Capitalized Contract Cost, Amortization 12 month |
|---|---|---|---|---|
| 2021-09-30 | $1.70M 10-Q · filed 2021-11-05 | $3.30M derived: sum of 2 quarters · filed 2021-11-05 | $3.30M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $1.60M 10-Q · filed 2021-07-30 | $1.60M 10-Q · filed 2021-07-30 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-11-05 | |||
| 2020-12-31 | $0.00 10-Q · filed 2021-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |